MARKET

ARWR

ARWR

Arrowhead Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

69.00
-0.56
-0.81%
After Hours: 69.00 0 0.00% 17:35 03/05 EST
OPEN
70.00
PREV CLOSE
69.56
HIGH
70.50
LOW
62.99
VOLUME
1.61M
TURNOVER
--
52 WEEK HIGH
92.60
52 WEEK LOW
19.51
MARKET CAP
7.16B
P/E (TTM)
-68.7388
1D
5D
1M
3M
1Y
5Y
DJ Arrowhead Seeks FDA OK for Phase 2b ARO-APOC3 Study in Hypertriglyceridemia >ARWR
Dow Jones · 5d ago
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s
Benzinga · 5d ago
Arrowhead Pharmaceuticals Submits Investigational New Drug Application to FDA For Hypertriglyceridemia Treatment
MT Newswires · 5d ago
Is Arrowhead Pharmaceuticals (ARWR) Stock a Buy For 2021?
Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020, the Baron Health Care Fund returned 17.1% (institutional shares). In comparison, the benchmark S&P 500 Inde...
Insider Monkey · 02/17 17:39
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Analysts Just Slashed This Year's Estimates
The analysts covering Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) delivered a dose of negativity to shareholders...
Simply Wall St. · 02/12 04:10
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11)
Benzinga · 02/11 12:26
ARWR: Multiple Data Readouts in 2021
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Multiple Catalysts in 2021 Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is developing medicines that cause gene silencing using RNA interference (RNAi), a specific means of i...
Zacks Small Cap Research · 02/09 15:24
DJ Arrowhead Pharmaceuticals Is Maintained at Buy by B. Riley FBR
Dow Jones · 02/08 17:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARWR. Analyze the recent business situations of Arrowhead Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARWR stock price target is 92.42 with a high estimate of 110.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 473
Institutional Holdings: 79.44M
% Owned: 76.54%
Shares Outstanding: 103.79M
TypeInstitutionsShares
Increased
91
3.80M
New
94
1.64M
Decreased
111
4.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Douglass Given
Chief Executive Officer/President/Director
Christopher Anzalone
Chief Financial Officer
Kenneth Myszkowski
Senior Vice President
James Hamilton
Chief Scientific Officer
Curt Bradshaw
Chief Compliance Officer/General Counsel/Secretary
Patrick O'Brien
Other
James Hassard
Other
Javier San Martin
Lead Director/Independent Director
Michael Perry
Independent Director
Marianne De Backer
Independent Director
Mauro Ferrari
Independent Director
Oye Olukotun
Independent Director
William Waddill
No Data
  • All
  • Financials
  • Insiders
More
About ARWR
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.